All AbbVie articles
-
BusinessPharmaceuticals roundup 2019
Under the shadow of political turmoil and major lawsuits, the industry returned to its strengths – making new drugs, and finding new ways to do it better
-
BusinessAbbVie to acquire Allergan in multibillion-dollar merger
Takeover deal will create world’s fifth-largest pharma company
-
ResearchGlass beads offer simple solution to dispensing tiny amounts of solids
Frustration drove chemists to overcome engineering challenge slowing high-throughput reaction screening set-ups
-
BusinessDeal protects world’s biggest selling drug from biosimilar erosion
AbbVie and Samsung Bioepis resolve patent litigation over arthritis drug Humira
-
FeatureSolvents and sustainability
Organic solvents make up a huge part of the waste from the chemical industry. Clare Sansom looks at efforts to reduce the loss or replace them entirely
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessLong road to recovery for Puerto Rico pharmaceuticals
As inhabitants begin to rebuild their lives after the devastation of hurricane Maria, the island’s drug manufacturers are recovering slowly
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
BusinessCancer deals spread
AbbVie nabs antibody specialist Stemcentrx, while Sanofi pursues Medivation
-
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
BusinessAbbVie to buy Pharmacyclics for pipeline boost
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
-
-
Business
AbbVie backs out of Shire deal
Treasury rule changes make inversion ‘too uncertain’ and remove financial benefits
-
BusinessPharma firms rush to escape US tax shackles
AbbVie–Shire and Mylan–Abbott mergers both allow US firms to escape to lower-tax European countries
-
BusinessEMA wrangles restrain trial data progress
Attempts to balance industry and research interests on transparency draw suggestions of improper collusion
-
Business
Shire fends off AbbVie takeover bid
Board says deal undervalues the company and its growth potential
-
BusinessJ&J puts trial data in independent hands
Yale University’s YODA seeks to help pharma avoid the dark side by acting as gatekeeper for patient records
-
